Clinical trial

Imatinib Mesylate and Docetaxel in Non-Small Cell Lung Cancer (NSCLC)

NCT01083589

Drugs and interventions used in this trial

2 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Mapped RxNorm record Imatinib Mesylate Normalized identity: imatinib mesylateView linked drug · Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record Docetaxel Normalized identity: docetaxelView linked drug · Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

Imatinib Mesylate and Docetaxel in Non-Small Cell Lung Cancer (NSCLC)

Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE2

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2005-01-01

PhasePHASE2

Conditions

Non-small Cell Lung Cancerverified · MONDO: non-small cell lung carcinoma

Interventions

Imatinib MesylateDRUG · verified · RxNorm: imatinib mesylate

DocetaxelDRUG · verified · RxNorm: docetaxel

Sponsors & collaborators

M.D. Anderson Cancer Centerlead sponsor

Novartiscollaborator

Mapped research locations

HoustonTexas, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT01083589 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.